Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet (London England). 2017;389(10086):2328–37.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.

Article  PubMed  Google Scholar 

Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.

Article  PubMed  Google Scholar 

O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human Disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.

Article  PubMed  PubMed Central  Google Scholar 

Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354–61.

Article  CAS  PubMed  Google Scholar 

van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.

Article  PubMed  Google Scholar 

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet (London England). 2013;381(9865):451–60.

Article  CAS  PubMed  Google Scholar 

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–62.

Article  CAS  PubMed  Google Scholar 

[2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua nei ke za zhi. 2018;57(4):242 – 51.

Fisher A, Hudson M, Platt RW, Dormuth CR. Canadian Network for Observational Drug Effect Studies I. Tofacitinib persistence in patients with rheumatoid arthritis: a retrospective cohort study. J Rheumatol. 2021;48(1):16–24.

Article  PubMed  Google Scholar 

Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: results from the RA-BEAM trial. J Clin Med. 2019;8(6).

Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clin Rheumatol. 2021;40(7):2673–80.

Article  PubMed  Google Scholar 

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8.

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet (London England). 2016;388(10055):2023–38.

Article  CAS  PubMed  Google Scholar 

Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–62.

Article  CAS  PubMed  Google Scholar 

Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25(4):514–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with Tofacitinib compared with Adalimumab, Etanercept, and Abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Managed care Specialty Pharm. 2016;22(12):1457–71.

Article  Google Scholar 

Mori S, Yoshitama T, Ueki Y. Tofacitinib Therapy for Rheumatoid Arthritis: a direct comparison study between Biologic-naïve and experienced patients. Intern Med (Tokyo Japan). 2018;57(5):663–70.

Article  CAS  Google Scholar 

Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95.

Article  CAS  PubMed  Google Scholar 

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–52.

Article  CAS  PubMed  Google Scholar 

Hernández-Cruz B, Rosas J, Díaz-Torné C, Belzunegui J, García-Vicuña R, Inciarte-Mundo J, et al. Real-world treatment patterns and clinical outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: results of a Multicenter, Observational Study in Routine Clinical Practice (the ORBIT-RA study). Rheumatol Therapy. 2022;9(2):589–608.

Article  Google Scholar 

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23.

Article  PubMed  Google Scholar 

Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022;18(5):485–93.

Article  CAS  PubMed  Google Scholar 

Ho Lee Y, Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther. 2020;45(4):674–81.

Article  CAS  PubMed  Google Scholar 

Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79(8):785–96.

Article  CAS  PubMed  Google Scholar 

Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021;80(9):1130–6.

Article  CAS  PubMed  Google Scholar 

Busch-Dienstfertig M, Gonzalez-Rodriguez S. IL-4, JAK-STAT signaling, and pain. JAKSTAT. 2013;2(4):e27638.

PubMed  Google Scholar 

Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and Disease development. Arthritis Res Therapy. 2012;14(5):R199.

Article  CAS  Google Scholar 

Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem. 2008;107(1):50–60.

Article  CAS  PubMed  Google Scholar 

Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic Drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1).

Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, et al. The Utility and limitations of CRP, ESR and DAS28-CRP in appraising Disease Activity in Rheumatoid Arthritis. Front Med. 2018;5:185.

Article  Google Scholar 

Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology (Oxford). 2021;60(9):4048–54.

Article  CAS  PubMed  Google Scholar 

Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34–i42.

Article  CAS  PubMed  Google Scholar 

Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–13.

Article  CAS  PubMed  Google Scholar 

Cohen SB. JAK inhibitors and VTE risk: how concerned should we be? Nat Rev Rheumatol. 2021;17(3):133–4.

Article  CAS  PubMed  Google Scholar 

Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein Thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774–80.

Article  PubMed  Google Scholar 

Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335–43.

Article  CAS  PubMed  Google Scholar 

Ozdede A, Yazici H. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(18):1766.

Article  PubMed  Google Scholar 

Comments (0)

No login
gif